Cannabis Law Report

NOVEMBER 23, 2021

The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. This is COMPASS’s 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JANUARY 12, 2022

OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. 14, 2021, the sale of Gb Sciences’ Las Vegas cannabis facility was finalized on Dec. LAS VEGAS, Jan.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

AUGUST 21, 2019

PUBLISHER: CANNABIS LAW REPORT. Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MMJ Recs

DECEMBER 22, 2023

As the United States navigates through a complex web of legal, social, and medical considerations, public opinion on medical cannabis has evolved significantly over the years. The changing public opinion is evident in the increasing number of states legalizing medical cannabis and the growing support for such measures.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

DECEMBER 9, 2021

Nue Life launched its proprietary nue.app on November 8 to increase access to psychedelic treatment as a catalyst for lasting change. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. MIAMI , Dec. ” About Nue Life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS 212-362-1200.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Contact: Tree of Knowledge International Corp. Natasha Raey. Natasha@tokicorp.com. 1.778.552.4538.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

DECEMBER 9, 2021

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Media Contact: media@mindmed.co. Investor Contact: ir@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Media Releases. Track Inquiry.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 11 × 11.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

JANUARY 13, 2020

Commence clinical program in PTSD. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

JUNE 24, 2021

The director was spoken to regarding psychedelics and cannabis by Senator Brian Schatz during a Senate Appropriations subcommittee hearing. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Doctors can prescribe Epidyolex – an oral solution of cannabidiol, which comes from the cannabis plant – if they think it will help sufferers. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Media: Liz Melone. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Stern Investor Relations, Inc.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

CannaMD

NOVEMBER 6, 2019

Using Cannabis to Quit Opioids. Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Results further indicate that the presence of medicinal cannabis legislation appears to have no influence over opioid misuse. million to 11.4

Marijuana 88

Marijuana Patients Clinical Trials Data 88

Cannabis Law Report

NOVEMBER 24, 2019

The growth and management of psychedelics regulation will be equally chaotic, but we think just as fast as the cannabis sector. The interview features a patient’s testimony after receiving treatment at the Center. Medium recently featured a piece on the treatment of Anorexia at the center. December 3, 2019. December 4, 2019.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 24, 2019

Marketwatch report… Shares of cannabis company Curaleaf Holdings Inc. 1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products.

CBD 51

CBD Tincture Pets Chronic Pain 51

The Blunt Truth

AUGUST 13, 2019

In each instance, the companies were selling products with flagrant disease-related claims that the FDA had not approved for the treatment or prevention of any ailments. 331(ll)), the FDA prohibits the sale of products containing an ingredient that has been treated as a drug or involved in clinical trials, without prior FDA approval.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JULY 23, 2019

This is particularly the case for cannabis and cannabidiol (CBD) products. As an example, the USPTO allows patents for cannabis inventions but prohibits registering trademarks for cannabis and cannabis products. Koi CBD, LLC is a cannabis company based in California. Laws on Legalised Cannabis.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

The Joint Blog

JULY 25, 2020

Cannabis has come a long way from being the taboo herb of decades past. Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. CBD is everywhere these days. CBD is found to be generally safe when consumed in prescribed portions.

CBD 33

CBD Clinical Trials Safety Media 33

The Cannigma

JUNE 24, 2021

Hemp and cannabis-derived medications may not be quite as mainstream as apple pie or multivitamins, but the days in which it was an almost completely illegal plant with little if any recognized medical benefits seem like a distant memory. That doesn’t mean that CBD or other cannabis products should be seen as a cure all on their own.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Info

OCTOBER 11, 2019

Cannabis & Dementia: New Study Explores Pot’s Potential for Treatment. In the decades since the medical marijuana movement began in earnest in the 1970s, cannabis has been anecdotally touted as an effective treatment for a variety of illnesses, including those impacting brain function, such as seizures, anxiety and depression.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

SEPTEMBER 29, 2021

ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com. . & LOS ANGELES–(BUSINESS WIRE)– ANANDA Scientific Inc. , An Investigational New Drug (IND) application is being submitted to the U.S.

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52